亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

医学 脂肪性肝炎 安慰剂 内科学 胃肠病学 脂肪变性 人口 临床终点 肝移植 肝活检 脂肪肝 外科
作者
Stephen A Harrison,Manal F Abdelmalek,Guy Neff,Nadege Gunn,Cynthia D Guy,Naim Alkhouri,Mustafa R Bashir,Bradley Freilich,Anita Kohli,Arun Khazanchi,Muhammad Y Sheikh,Mark Leibowitz,Mary E Rinella,Mohammad S Siddiqui,Mark Kipnes,Sam E Moussa,Ziad H Younes,Meena Bansal,Seth J Baum,Brian Borg,Peter J Ruane,Paul J Thuluvath,Mildred Gottwald,Mujib Khan,Charles Chen,Liza Melchor-Khan,William Chang,Alex M DePaoli,Lei Ling,Hsiao D Lieu
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
标识
DOI:10.1016/s2468-1253(22)00017-6
摘要

Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, and injury, and is associated with an increased risk of liver transplantation and death. NASH affects more than 16 million people in the USA, and there is no approved therapy. The aim of this study was to evaluate the safety and efficacy of aldafermin, an engineered analogue of the gut hormone fibroblast growth factor 19 (FGF19).In this randomised, double-blind, placebo-controlled, phase 2b study (ALPINE 2/3) in patients with biopsy-confirmed NASH and stage 2 or 3 fibrosis, we randomly assigned patients stratified by fibrosis stage in a 1:1:1:1 ratio to receive placebo, aldafermin 0·3 mg, 1·0 mg, or 3·0 mg once daily for 24 weeks at 30 study sites in the USA. Patients, investigators, the funder, and all other staff, were masked to treatment assignment throughout the study. The primary endpoint was an improvement in liver fibrosis of at least one stage with no worsening of NASH at week 24. Analyses were done by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT03912532, and has been completed.Between May 16, 2019, and Sept 4, 2020, 786 patients were screened, of whom 171 were randomly assigned to a treatment group and included in the intention-to-treat population: 43 in the 0·3 mg aldafermin group, 42 in the 1·0 mg group, 43 in the 3·0 mg group, and 43 in the placebo group. In total, 145 (85%) of patients completed treatment. At week 24, among patients with biopsies at both baseline and week 24, was seven (19%) of 36 patients in the placebo group, 11 (31%) of 36 in the 0·3 mg aldafermin group (difference 90% CI 12% [-9 to 33]; p=0·11), five (15%) of 34 patients in the 1·0 mg group (difference -5% [-24 to 13]; p=0·80), and 11 (30%) of 37 patients in the 3·0 mg group (difference 10% [-9 to 30]; p=0·12) had an improvement in liver fibrosis of at least one stage with no worsening of NASH, without meeting the prespecified significance for dose response (p=0·55). Adverse events were mostly mild or moderate in severity. Diarrhoea occurred in six (14%) of 43 patients in the placebo group, three (7%) of 43 patients in the 0·3 mg aldafermin group, five (12%) of 41 patients in the 1·0 mg group, and ten (23%) of 43 patients in the 3·0 mg group. Incidences of serious adverse events and discontinuations owing to adverse events were similar between groups.Aldafermin was generally well tolerated but did not produce a significant dose response on fibrosis improvement of at least one stage with no worsening of NASH, despite positive effects on a number of secondary endpoints. The findings of this trial may have implications for the design of future NASH trials.NGM Biopharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈龙完成签到,获得积分10
1秒前
aa完成签到,获得积分10
5秒前
LSQ完成签到,获得积分10
12秒前
18秒前
foden完成签到,获得积分10
19秒前
xinran完成签到,获得积分10
24秒前
温暖的帆布鞋完成签到,获得积分10
27秒前
yli130完成签到,获得积分10
28秒前
28秒前
34秒前
Sarahminn发布了新的文献求助10
35秒前
37秒前
俏皮的灵发布了新的文献求助10
38秒前
机灵的沂完成签到,获得积分10
50秒前
奔跑的应助被虚心的灵寒采纳,获得10
51秒前
奔跑的应助被虚心的灵寒采纳,获得10
51秒前
欢呼的兰完成签到,获得积分10
54秒前
华仔的应助被lmn采纳,获得10
58秒前
酒酿是也完成签到 ,获得积分10
58秒前
满意的楷瑞完成签到,获得积分10
1分钟前
顺利的水瑶完成签到 ,获得积分10
1分钟前
1分钟前
我是老大的应助被科研通管家采纳,获得10
1分钟前
彭于晏的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
慕青的应助被肖可声采纳,获得10
1分钟前
田様的应助被重要白亦采纳,获得10
1分钟前
科研通AI6.2的应助被Jeff采纳,获得20
1分钟前
科研通AI6.3的应助被Jeff采纳,获得50
1分钟前
烟花的应助被俏皮的灵采纳,获得10
1分钟前
lmn发布了新的文献求助10
1分钟前
1分钟前
Maestro_S的应助被Kaikai采纳,获得10
1分钟前
1分钟前
肖可声完成签到,获得积分10
1分钟前
mino完成签到 ,获得积分10
1分钟前
1分钟前
肖可声发布了新的文献求助10
1分钟前
铃木完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571